Compare VERU & AMPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | AMPG |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 51.7M |
| IPO Year | 1996 | N/A |
| Metric | VERU | AMPG |
|---|---|---|
| Price | $2.92 | $9.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $7.00 |
| AVG Volume (30 Days) | 5.2M | ★ 7.5M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,296,958.00 | N/A |
| Revenue This Year | N/A | $102.41 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $1.64 |
| 52 Week High | $7.33 | $10.11 |
| Indicator | VERU | AMPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 69.51 |
| Support Level | $2.15 | $2.56 |
| Resistance Level | $3.68 | N/A |
| Average True Range (ATR) | 0.67 | 1.32 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 15.52 | 80.59 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.